Clinical Trial

The Distribution of Immunoglobulin Isotype in Polyclonal Hypergammaglobulinemia in Systemic and Autoimmune Diseases

Study acronym: ISOHYPE
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 10, 2024 (before its estimated August 2024 completion). Its status may not reflect the trial's current state.
Summary
Polyclonal hypergammaglobulinaemia is characterized by increased levels of immunoglobulins and is a common feature observed in various diseases such as autoimmune diseases, chronic infectious diseases or lymphoid hemopathy. Some autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis or Sjögren's syndrome are frequently associated with polyclonal hypergammaglobulinaemia. Recent data have suggested that the distribution of immunoglobulin isotypes in polyclonal hypergammaglobulinaemia may be disease-specific. However, isotype repartition in polyclonal hypergammaglobulinaemia remains poorly understood. The investigators will investigate the distribution of immunoglobulin isotype in patients with autoimmune disease and polyclonal hypergammaglobulinaemia. Moreover, the investigators will evaluate the isotype repartition as predictor of lymphoma or monoclonal gammopathy among patients with autoimmune diseases.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06054373
Lead Sponsor Centre Hospitalier Universitaire, Amiens
Collaborators: Binding site
Conditions Polyclonal Hypergammaglobulinemia, Autoimmune Diseases
Enrollment 150 participants
Start Date 2023-07-27
Primary Completion 2024-08 (estimated)
Study Completion 2024-09 (estimated)
Updated on ClinicalTrials.gov 2024-07-10